Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

TAMSULOSIN-TEVA PROLONGED RELEASE FILM-COATED TABLET 400MCG [SIN16191P]

Active ingredients: TAMSULOSIN-TEVA PROLONGED RELEASE FILM-COATED TABLET 400MCG

View product's general information
Last updated 24 April 2026

Product Info

TAMSULOSIN-TEVA PROLONGED RELEASE FILM-COATED TABLET 400MCG

[SIN16191P]

Product information

Active Ingredient and Strength

TAMSULOSIN EQV TAMSULOSIN HYDROCHLORIDE - 0.4 MG

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Manufacturer and Country

TEVA PHARMACEUTICAL WORKS PRIVATE LIMITED COMPANY - HUNGARY

Registration Number

SIN16191P

Licence Holder

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

G04CA02

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

INDICATIONS
For the relief of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).

Dosing

DOSAGE AND ADMINISTRATION
One tablet daily.

The tablet must be swallowed whole and not be broken, crunched or chewed, as this compromises the prolonged release properties of the tablet for the active ingredient. Tamsulosin hydrochloride tablet can be taken on an empty stomach, or before, with or after food.

Contraindications

CONTRAINDICATIONS

  • Hypersensitivity to tamsulosin hydrochloride, including drug-induced angioedema or any other component of the product.

  • A history of orthostatic hypotension.

  • Severe hepatic impairment (Child-Pugh scores >9).

  • Severe renal impairment with creatinine clearance of less than 10mL/min.

  • Concurrent use of another α1-adrenoceptor inhibitor.